Intrinsic Value of S&P & Nasdaq Contact Us
English English 中文(简) 中文(简) 中文(繁) 中文(繁) हिन्दी हिन्दी Español Español 日本語 日本語 한국어 한국어 Deutsch Deutsch Français Français
← Back to all stocks

Pieris Pharmaceuticals, Inc. PIRS NASDAQ

NASDAQ Capital Marke • Healthcare • Biotechnology • US • USD

SharesGrow Score
36/100
1/5 Pass
SharesGrow Intrinsic Value
N/A
Negative cash flow

Pieris Pharmaceuticals, Inc. (PIRS) is a Biotechnology company in the Healthcare sector, currently trading at $13.60. It has a SharesGrow Score of 34/100, indicating a weak investment profile with 1 out of 7 criteria passed.

Net income is $42M (loss), growing at -29.6%/yr. Net profit margin is 0% (thin). Gross margin is 2.4% (-86.9 pp trend).

Balance sheet: total debt is $633,000 against $28M equity (Debt-to-Equity (D/E) ratio 0.02, conservative). Current ratio is 5.2 (strong liquidity). Debt-to-assets is 1.1%. Total assets: $60M.

Analyst outlook: 2 / 2 analysts rate PIRS as buy (100%) — strong consensus.

SharesGrow 7-Criteria breakdown: Value ?/100 (Fail), Growth 15/100 (Fail), Past 0/100 (Fail), Health 67/100 (Partial), Moat 0/100 (Fail), Future 100/100 (Pass), Income ?/100 (Fail).

PIRS SharesGrow Score Overview

61/100
SharesGrow Score
Above average fundamentals
View full scorecard →
VALUE 0/100
Valuation — P/E, PEG, Forward PEG
GROWTH 15/100
Financials — average growth
PAST 0/100
strong — trend
HEALTH 67/100
Balance sheet — Debt-to-Equity (D/E) ratio, Current ratio is
MOAT 0/100
Gross margin is + market cap
FUTURE 100/100
Analyst outlook — as buy
INCOME 0/100
Net profit margin is
Scores derived from financial statements, analyst ratings, and balance sheet data.

Score Breakdown — PIRS

—
VALUE N/A
N/A
No analyst coverage available for this stock.
✗
GROWTH Fail
15/100
PIRS: -17.4%/yr revenue is, -29.6%/yr Net income is average growth. weak. Score: >20%/yr = 100, >10% = 80, >5% = 65, >0% = 45, < 0 = 15.
View details →
—
PAST N/A
N/A
No analyst coverage available for this stock.
~
HEALTH Partial
67/100
Balance sheet PIRS: Debt-to-Equity (D/E) ratio 0.02 (conservative), Current ratio is 5.2 (strong liquidity). Debt-to-Equity < 0.5, Current Ratio > 1.5, Interest Coverage > 8x = ideal. ≥ 70 = Pass.
View details →
—
MOAT N/A
N/A
No analyst coverage available for this stock.
✓
FUTURE Pass
100/100
Analyst outlook: 2 / 2 analysts rate PIRS as buy (100%). Score: 60% buy consensus + 40% upside. ≥ 60 = Pass.
View details →
—
INCOME N/A
N/A
No analyst coverage available for this stock.

Stock Chart & Stats

Market Data
52-Week Range6.2-22.32
Volume51.73K
Avg Volume (30D)22.13K
Market Cap$17.96M
Beta (1Y)0.66
Share Statistics
EPS (TTM)-3.71
Shares Outstanding$11.25M
IPO Date2015-01-02
Employees46
CEOStephen S. Yoder
Financial Highlights & Ratios
Net Income$-41.72M
Total Cash$57.98M
Total Debt$633K
Net Debt$-57.35M
Total Assets$59.56M
Price / Earnings (P/E)-3.7
Analyst Forecast
Rating ConsensusBuy
Analysts Covering2
Buy 100% Hold 0% Sell 0%
Company Info
CountryUS
ExchangeNASDAQ Capital Marke
CurrencyUSD
ISINUS7207951036

Price Chart

Track all markets on TradingView
PIRS
Pieris Pharmaceuticals, Inc. ↗  ·  NASDAQ Capital Marke
Healthcare • Biotechnology
6.20 52WK RANGE 22.32

People Also View

TERN
TERN
Terns Pharmaceuticals, Inc.
$52.71
+0.06%
 CRVS
CRVS
Corvus Pharmaceuticals, Inc.
$15.11
-0.92%
 ADCT
ADCT
ADC Therapeutics S.A.
$4.37
+13.21%
 CKPT
CKPT
Checkpoint Therapeutics, Inc.
$4.26
+0.00%
 INZY
INZY
Inozyme Pharma, Inc.
$4.00
+0.25%
 AGEN
AGEN
Agenus Inc.
$4.83
+2.33%
 PDSB
PDSB
PDS Biotechnology Corporation
$1.36
+28.30%
 ADAP
ADAP
Adaptimmune Therapeutics plc
$0.05
-3.00%
Contact Us
🎓
SharesGrow Academy
Learn how to calculate Intrinsic Value and find undervalued stocks.
Weekly live sessions
📧 [email protected]
📞 +65 8912 8000
Send us a message